| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Hypoxanthine-guanine phosphoribosyltransferase (HGPRT). 9-Deazaguanine is a potent inhibitor of HGPRT, the enzyme that catalyzes the conversion of hypoxanthine and guanine to their respective nucleotides in the purine salvage pathway. By inhibiting HGPRT, the compound disrupts purine nucleotide synthesis, which can affect DNA and RNA synthesis, cell proliferation, and immune function. The compound's mechanism of action involves binding to the active site of HGPRT and preventing the conversion of guanine to GMP.
|
|---|---|
| ln Vitro |
9-Deazaguanine inhibits HGPRT activity, disrupting purine nucleotide synthesis. The compound has been studied for its potential antimalarial, anticancer, and immunosuppressive activities. By inhibiting purine salvage, it can affect cell proliferation and immune cell function. Its specific in vitro activities depend on the concentrations tested and the assay systems used. The compound's inhibitory activity can be measured using enzyme assays with purified HGPRT.
|
| ln Vivo |
In vivo studies of 9-deazaguanine are limited. As an HGPRT inhibitor, it may have potential applications in malaria, cancer, and immunosuppression. The compound may be evaluated in animal models of these diseases. Further in vivo studies are needed to characterize its specific pharmacokinetic and pharmacodynamic properties, as well as its efficacy and safety profile.
|
| Enzyme Assay |
Non-cell-based assays for 9-deazaguanine include HGPRT enzyme inhibition assays using purified enzyme. The enzyme is incubated with hypoxanthine or guanine and PRPP in the presence of various concentrations of 9-deazaguanine, and enzyme activity is measured by detecting the formation of nucleotides using HPLC or radiometric methods. The IC₅₀ value is calculated from the dose-response curve. Standard analytical methods including HPLC, NMR, and mass spectrometry are used for compound characterization.
|
| Cell Assay |
Cell-based assays for 9-deazaguanine use various cell lines to assess its biological activities. Cells are treated with the compound, and purine nucleotide levels are measured using HPLC or LC-MS. Cell proliferation is assessed using MTT or similar assays. For antimalarial studies, Plasmodium-infected erythrocytes are used. For immunosuppressive studies, T cell proliferation and cytokine production are assessed. Apoptosis is evaluated by flow cytometry.
|
| Animal Protocol |
In vivo studies of 9-deazaguanine are limited. Based on its biological activities, potential animal models include: malaria models for antimalarial evaluation; tumor xenograft models for anticancer evaluation; and transplantation models for immunosuppressive evaluation. Standard protocols for these models involve administration of the compound followed by measurement of relevant endpoints.
|
| ADME/Pharmacokinetics |
9-Deazaguanine has a molecular formula of C₆H₆N₄O and a molecular weight of approximately 150.14 g/mol. The CAS number is 65996-58-9. It is a purine analog structurally related to guanine but lacking the nitrogen atom at the 9-position. The compound is an inhibitor of HGPRT. It should be stored under recommended conditions. It is intended for research use only.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for 9-deazaguanine are limited. As a purine analog that inhibits purine metabolism, it may have effects on rapidly dividing cells including immune cells and bone marrow cells. Standard laboratory safety practices should be followed when handling this compound, including the use of personal protective equipment. It is intended for research use only.
|
| References |
[1]. Beata Wielgus-Kutrowska, et al. Trimeric purine nucleoside phosphorylase: exploring postulated one-third-of-the-sites binding in the transition state. Bioorg Med Chem. 2012 Nov 15;20(22):6758-69.
|
| Additional Infomation |
9-Deazaguanine is a purine analog and a potent inhibitor of the enzyme hypoxanthine-guanine phosphoribosyltransferase (HGPRT). HGPRT is involved in the purine salvage pathway, which is essential for nucleotide synthesis in certain cells and organisms including Plasmodium parasites. By inhibiting HGPRT, the compound disrupts purine nucleotide synthesis, affecting DNA and RNA synthesis, cell proliferation, and immune function. 9-Deazaguanine has been studied for its potential antimalarial, anticancer, and immunosuppressive activities. It is used as a research tool for studying purine metabolism and as a reference standard. It is for research use only.
|
| Molecular Formula |
C6H6N4O
|
|---|---|
| Molecular Weight |
150.14
|
| Exact Mass |
150.054
|
| CAS # |
65996-58-9
|
| PubChem CID |
135461003
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.87g/cm3
|
| Boiling Point |
452.7ºC at 760mmHg
|
| Flash Point |
227.6ºC
|
| Index of Refraction |
1.89
|
| LogP |
0.414
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
11
|
| Complexity |
225
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C1C2=C(C([H])=C([H])N2[H])N=C(N([H])[H])N1[H]
|
| InChi Key |
FFYPRJYSJODFFD-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C6H6N4O/c7-6-9-3-1-2-8-4(3)5(11)10-6/h1-2,8H,(H3,7,9,10,11)
|
| Chemical Name |
2-amino-3,5-dihydropyrrolo[3,2-d]pyrimidin-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 3.33 mg/mL (22.18 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.6605 mL | 33.3023 mL | 66.6045 mL | |
| 5 mM | 1.3321 mL | 6.6605 mL | 13.3209 mL | |
| 10 mM | 0.6660 mL | 3.3302 mL | 6.6605 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
